155 related articles for article (PubMed ID: 10810467)
21. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic targeting of osteoclast function and pathways.
Broadhead ML; Clark JC; Dass CR; Choong PF; Myers DE
Expert Opin Ther Targets; 2011 Feb; 15(2):169-81. PubMed ID: 21204734
[TBL] [Abstract][Full Text] [Related]
23. Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites.
Abdelaziz DM; Stone LS; Komarova SV
Breast Cancer Res Treat; 2015 Aug; 153(1):9-20. PubMed ID: 26208488
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
25. Ewing sarcoma cells express RANKL and support osteoclastogenesis.
Taylor R; Knowles HJ; Athanasou NA
J Pathol; 2011 Oct; 225(2):195-202. PubMed ID: 21547906
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
27. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
28. M-CSF mediates TNF-induced inflammatory osteolysis.
Kitaura H; Zhou P; Kim HJ; Novack DV; Ross FP; Teitelbaum SL
J Clin Invest; 2005 Dec; 115(12):3418-27. PubMed ID: 16294221
[TBL] [Abstract][Full Text] [Related]
29. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
[TBL] [Abstract][Full Text] [Related]
30. Osteoclast formation during tumor osteolysis does not require proliferating osteoclast precursor cells.
Clohisy DR; Ramnaraine ML
J Orthop Res; 1997 Mar; 15(2):301-6. PubMed ID: 9167635
[TBL] [Abstract][Full Text] [Related]
31. Bone resorption and bone metastasis risk.
Mathis KM; Sturgeon KM; Winkels RM; Wiskemann J; De Souza MJ; Schmitz KH
Med Hypotheses; 2018 Sep; 118():36-41. PubMed ID: 30037612
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-mediated in vivo bone resorption.
Maitra R; Follenzi A; Yaghoobian A; Montagna C; Merlin S; Cannizzo ES; Hardin JA; Cobelli N; Stanley ER; Santambrogio L
J Immunol; 2010 Aug; 185(3):1485-91. PubMed ID: 20581147
[TBL] [Abstract][Full Text] [Related]
33. Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas.
Kulenkampff HA; Dreyer T; Kersjes W; Delling G
Virchows Arch A Pathol Anat Histopathol; 1986; 409(6):817-28. PubMed ID: 3094242
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor.
Morgan H; Tumber A; Hill PA
Int J Cancer; 2004 May; 109(5):653-60. PubMed ID: 14999770
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
[TBL] [Abstract][Full Text] [Related]
36. Non-bone metastatic cancers promote osteocyte-induced bone destruction.
Pin F; Prideaux M; Huot JR; Essex AL; Plotkin LI; Bonetto A; Bonewald LF
Cancer Lett; 2021 Nov; 520():80-90. PubMed ID: 34233150
[TBL] [Abstract][Full Text] [Related]
37. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model.
Ren W; Markel DC; Schwendener R; Ding Y; Wu B; Wooley PH
J Biomed Mater Res A; 2008 Jun; 85(4):1043-51. PubMed ID: 17937417
[TBL] [Abstract][Full Text] [Related]
38. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
[TBL] [Abstract][Full Text] [Related]
39. Deletion of FGFR3 in Osteoclast Lineage Cells Results in Increased Bone Mass in Mice by Inhibiting Osteoclastic Bone Resorption.
Su N; Li X; Tang Y; Yang J; Wen X; Guo J; Tang J; Du X; Chen L
J Bone Miner Res; 2016 Sep; 31(9):1676-87. PubMed ID: 26990430
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice.
Iwasaki T; Yamashita K; Tsujimura T; Kashiwamura S; Tsutsui H; Kaisho T; Sugihara A; Yamada N; Mukai M; Yoneda T; Okamura H; Akedo H; Terada N
J Immunother; 2002; 25 Suppl 1():S52-60. PubMed ID: 12048351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
